Office of Health and Constituent Affairs
Food and Drug Administration
U.S. Department of Health and Human Services
Food and Drug Administration
U.S. Department of Health and Human Services
March 15, 2017
Dear Colleague,
On April 6, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the impact of sarcopenia on daily life and patient views on treatment approaches.
Date: April 6, 2017
Time: 1:00 p.m. - 5:00 p.m. (EDT)
Location: Tommy Douglas Conference Center
10000 New Hampshire Avenue
Silver Spring, MD 20903
10000 New Hampshire Avenue
Silver Spring, MD 20903
Registration: To register for this meeting, visit: Patient-Focused Drug Development Public Meeting for Sarcopenia Event Brite website.
Public Docket: In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.
FDA is interested in patient responses to the questions listed in the Federal Register Notice.
Sincerely,
Andrea C. Furia-Helms, M.P.H.
On April 6, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia. FDA is interested in obtaining patient perspectives on the on the impact of sarcopenia on daily life and patient views on treatment approaches.
Date:
April 6, 2017
Time:
1:00 p.m. - 5:00 p.m.
Location:
Tommy Douglas Conference Center
10000 New Hampshire Ave.
Silver Spring, MD 20903
10000 New Hampshire Ave.
Silver Spring, MD 20903
Registration:
To register for this meeting, visit: Patient-Focused Drug Development Public Meeting for Sarcopenia Event Brite
website.
website.
Registration to attend the meeting must be received by April 6, 2017.
Public Docket:
In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 6, 2017.
- FDA is interested in patient responses to the questions listed in the Federal Register Notice.
- Access the public docket here: Docket Information
.png)
No hay comentarios:
Publicar un comentario